Jasmine Li and Sudha Rao (The John Curtin School of Medical Research, Canberra, Australia).

“Study of the role of PKCtheta on HIV-1 replication in CD4+ T cells and its interaction with the viral elongator factor Tat”.

Sunil K Arora (Post-Graduate Institute of Medical Education and Research, PGIMER, Chandigarh, India)

“Characterization of viral tropism in viral isolates from India and assessment of the antiviral activity of isolated lectins”.

 

 

 

Felipe García, Teresa Gallart and Josep María Gatell (Hospital Clínic, Barcelona, Spain).

 “Development of new therapeutic vaccines based on dendritic cells.”

Peña J, Frías M, Castro-Orgaz L, González R, García F, Gallart T, Gatell JM, Plana M; Dc2-Manon07 Vaccine Research Group. Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection.Viral Immunol. 2012 Feb;25(1):37-44.

García F, Climent N, Assoumou L, Gil C, González N, Alcamí J, León A, Romeu J, Dalmau J, Martínez-Picado J, Lifson J, Autran B, Costagliola D, Clotet B, Gatell JM, Plana M, Gallart T; DCV2/MANON07- AIDS Vaccine Research Objective Study Group. A therapeutic dendritic cell-based vaccine for HIV-1 infection.J Infect Dis. 2011 Feb 15;203(4):473-8.

García F, Lejeune M, Climent N, Gil C, Alcamí J, Morente V, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.J Infect Dis. 2005 May 15;191(10):1680-5.

 

 

Fernando Arenzana-Seisdedos and Bernard Lagane (Unité de Pathogénie Virale, Institut Pasteur, Paris, France).

“Interaction of chemokines and their receptors and their role in driving HIV-1 selection.”

García-Pérez J, Rueda P, Alcamí J, Rognan D, Arenzana-Seisdedos F, Lagane B, et al. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).J Biol Chem. 2011 Sep 23;286(38):33409-21.

García-Pérez J, Rueda P, Staropoli I, Kellenberger E, Alcamí J, Arenzana-Seisdedos F, et al. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.J Biol Chem. 2011 Feb 18;286(7):4978-90.

 

Sonsoles Sánchez-Palomino and Montse Plana (Hospital Clínic, Barcelona, Spain).

“Development of new HIV-1 based vectors for vaccine use.”

Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández MA, et al. Safety and immunogenicity of a MVA-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. In press.

Guardo AC, Álvarez-Fernández C, Arberas H, García-Pérez J, García F, Bargalló ME, et al. Use of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individuals. PLoS One. 2013;8(3):e58927.

Álvarez-Fernández C, Crespo Guardo A, García-Pérez J, García F, Blanco J, Escribà-García L, et al. Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine. PLoS One. 2012;7(11):e48848.

 

 

Monsef Benkirane (Institut de Génétique Humaine, Montpellier, France).

“Regulation of SAMHD1 in CD4 lymphocytes.”

 

Fabrizio Mammano (Hôpital St Louis, Paris, France).

“Regulation of HIV-1 accessory genes by Interferon treatment in vivo.”

 

Jorge del Romero (Centro Sanitario Sandoval, Madrid, Spain) and José María Miró (Hospital Clínic, Barcelona, Spain).

“Characterization of molecular and functional fingerprints in envelopes from founder viruses.”

 

Carolina Herrera and Robin Shattock (Imperial College, London, UK).

“Development of new microbicides based on Maraviroc combinations.”

 

 

Richard Koup (Vaccine Research Center, NIH, Maryland, USA) and Eloísa Yuste (Hospital Clínic, Barcelona, Spain).

“Characterization of anti-HIV antibodies from Elite Neutralizers and Long Term Non-Progressor.”

Medina-Ramírez M, Sánchez-Merino V, Sánchez-Palomino S, Merino-Mansilla A, Ferreira CB, Pérez I, et al. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.J Virol. 2011 Jun;85(12):5804-13.

 

Anavaj Sakuntabai (Functional Genetics of Infectious Diseases Unit, Institut Pasteur, Paris).

“Genomic studies in Long Term Non-Progressors.”

 

 

Juan Jesús Vilchez (Hospital La Fe, Valencia, Spain), Antonio Andreu and Ramón Martí (Vall d'Hebron Institut de Recerca, Barcelona, Spain).

“Characterization of an in vivo defect in Transportin 3 and its impact on HIV-1 infection.”

 

Jesús Vázquez and Juan Antonio López (Centro Nacional de Investigaciones Cardiovasculares - CNIC, Madrid, Spain).

“Proteomic analysis of cell expressing the HIV-1 Tat protein.”

López-Huertas MR, Mateos E, Sánchez Del Cojo M, Gómez-Esquer F, Díaz-Gil G, Rodríguez-Mora S, et al. The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4+ T lymphocytes: a potential mechanism for persistent viral production.J Biol Chem. 2013 Mar 15;288(11):7626-44.

Coiras M, Camafeita E, López-Huertas MR, Calvo E, López JA, Alcamí J. Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents.Proteomics. 2008 Feb;8(4):852-73.

Coiras M, Camafeita E, Ureña T, López JA, Caballero F, Fernández B, et al. Modifications in the human T cell proteome induced by intracellular HIV-1 Tat protein expression.Proteomics. 2006 Apr;6 Suppl 1:S63-73.

 

Carles Suñé (Instituto de Parasitología y Biomedicina “López - Neyra”, Granada, Spain).

“Characterization of TCERG function and its role in HIV-1 replication.”

Coiras M, Montes M, Montanuy I, López-Huertas MR, Mateos E, Le Sommer C, et al. Transcription elongation regulator 1 (TCERG1) regulates competent RNA polymerase II-mediated elongation of HIV-1 transcription and facilitates efficient viral replication.Retrovirology. 2013 Oct 28;10(1):124.

 

Isabel López Bazochi (Universidad de La Laguna, Canarias, Spain).

“Characterization of new compounds targetting HIV-1 latency and morphogenesis.”

Osorio AA, Muñoz A, Torres-Romero D, Bedoya LM, Perestelo NR, Jiménez IA, et al. Olean-18-ene triterpenoids from Celastraceae species inhibit HIV replication targeting NF-kB and Sp1 dependent transcription.Eur J Med Chem. 2012 Jun;52:295-303.

 

 

José Gallego (Universidad Católica de Valencia, Valencia, Spain).

“New compounds targeting Rev-RRE interactions.”

González-Bulnes L, Ibáñez I, Bedoya LM, Beltrán M, Catalán S, Alcamí J, et al. Structure-based design of an RNA-binding p-terphenylene scaffold that inhibits HIV-1 Rev protein function.Angew Chem Int Ed Engl. 2013 Dec 9;52(50):13405-9.

 

Soledad Penadés (CIC BiomaGUNE, San Sebastián, Spain).

“Multivalent manno-glyconanoparticles as platforms against HIV-1 infection.”

Di Gianvincenzo P, Marradi M, Martínez-Ávila OM, Bedoya LM, Alcamí J, Penadés S. Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents.Bioorg Med Chem Lett. 2010 May 1;20(9):2718-21.

Martínez-Ávila O, Bedoya LM, Marradi M, Clavel C, Alcamí J, Penadés S. Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T cells.Chembiochem. 2009 Jul 20;10(11):1806-9.

 

 

Rafael Sanjuán (Instituto Cavanilles de Biodiversidad y Biología Evolutiva, Universitat de València, Valencia, Spain).

“Evolution of immune responses against HIV-1 infection.”

Sanjuán R, Nebot MR, Peris JB, Alcamí J. Immune activation promotes evolutionary conservation of T-cell epitopes in HIV-1.PLoS Biol. 2013;11(4):e1001523.

 

Roger Le Grand (CEA, Fontenay les Roses, France), Guido Poli and Elisa Vicenzi (Università Vita-Salute San Raffaele, Milan, Italia).

“Development of a new class of microbicides.”